Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop (Q37359948)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 1996

Language	Label	Description	Also known as
English	Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop	scientific article published on September 1996

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Henk M. Lokhorst

7

object named as

Lokhorst HM

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

van Zaanen HC

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Koopmans RP

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Aarden LA

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Rensink HJ

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Stouthard JM

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Warnaar SO

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

van Oers MH

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

1 September 1996

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Clinical Investigation

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

98

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1441-1448

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

Interleukin-6 and the acute phase response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

6 September 2017

Cytokine-binding proteins: stimulating antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

14 September 2017

Interleukin-6, a new target for therapy in multiple myeloma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

28 September 2017

Production of hybridoma growth factor by human monocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

Response patterns of purified myeloma cells to hematopoietic growth factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

26 June 2018

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

2 September 2018

Anticipating, recognizing, and preventing hazards associated with in vivo use of monoclonal antibodies: special considerations related to human anti-mouse antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507571

2 September 2018

Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fate of interleukin-6 in the rat. Involvement of skin in its catabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1

1 reference

https://pubmed.ncbi.nlm.nih.gov/8823310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1172/JCI118932

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37359948&oldid=2214101752"